Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+25
- Incentives
- Insufficient
- Confidence40
Japan's obesity society warned cosmetic GLP-1 users of side-effect risks, as 35 of about 950 Mounjaro side-effect reports involved dieting or cosmetic use. The health ministry separately said the drugs should not be used casually as weight-loss pills.
Reality
- Evidence50
- Adoption
- Insufficient
- Hype gap+5
- Incentives
- Insufficient
- Confidence55
Korea's grey channel for weight-loss drugs now dwarfs the licensed one by case count, and a foreign web price that domestic prescriptions cannot match is doing the work.
Reality
- Evidence68
- Adoption
- Insufficient
- Hype gap+20
- Incentives40
- Confidence62
One personal injury firm has filed more than 90 New Jersey suits claiming Novo Nordisk's Ozempic and Wegovy caused sudden vision loss. Denmark has awarded about $55,600 a patient for the same injury, the only price on record, while studies of whether the drugs cause it still disagree.
Reality
- Evidence45
- Adoption
- Insufficient
- Hype gap+10
- Incentives65
- Confidence50
Prescribing has outrun the approval label for US children aged 8 to 11 with obesity. The trial behind the benefit claim followed them for 68 weeks. Those 68 weeks are the entire developmental record so far.
Reality
- Evidence50
- Adoption72
- Hype gap+14
- Incentives62
- Confidence55
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
- Evidence45
- Adoption74
- Hype gap+14
- Incentives62
- Confidence42
More than 90 New Jersey suits and dozens more against Novo Nordisk and Eli Lilly turn on a warning the FDA has not written while four other jurisdictions added theirs. Denmark's payouts are the only money that has moved so far.
Reality
- Evidence45
- Adoption55
- Hype gap+20
- Incentives65
- Confidence45
The Danish drugmaker will test Anthropic's science workbench on specific R&D workflows while an earlier company-wide OpenAI agreement keeps running alongside it. Bloomberg reported that financial terms were not disclosed.
Reality
- Evidence52
- Adoption22
- Hype gap+45
- Incentives82
- Confidence58
The Federal Reserve says reaching customers is the top operational problem for small employers. One owner's account suggests part of that problem is detection, and the proximity that catches such signals is the first thing growth takes away.
Reality
- Evidence34
- Adoption
- Insufficient
- Hype gap+18
- Incentives55
- Confidence44
The Bridge pilot prices by FDA label rather than medical need, routing sicker patients back to Part D copays. KFF's own math assumes three of four eligible people never enroll.
Reality
- Evidence58
- Adoption34
- Hype gap+18
- Incentives66
- Confidence52
A national survey of 27,741 adults reports 1.9 times the depression among prescribed weight-loss drug users, and 4.2 times the suicidal ideation among those who regained weight. The exposed group is 3% of the sample.
Reality
- Evidence34
- Adoption66
- Hype gap+41
- Incentives44
- Confidence33
A 2026 JAMA Surgery analysis shows surgical obesity care losing a third of its volume in two years. The spend has not vanished; it has moved to the pharmacy benefit, where coverage decides who gets treated.
Reality
- Evidence56
- Adoption74
- Hype gap+14
- Incentives66
- Confidence54
Nagoya University and FUJIFILM report longer-lasting expression from capped circular RNA in a new lipid nanoparticle. The mouse data are directional; the duration numbers are not public yet.
Reality
- Evidence42
- Adoption
- Insufficient
- Hype gap+34
- Incentives62
- Confidence40
An advisory panel voted to route peptides marketed for sleep, wound healing and cognition through compounding pharmacies, which face less oversight and may dispense unapproved drugs.
Reality
- Evidence60
- Adoption45
- Hype gap+35
- Incentives70
- Confidence50
The runners-up behind Lilly and Novo are consolidating around a few late-stage assets. Readouts starting next year, not messaging, will decide who takes share.
Reality
- Evidence32
- Adoption24
- Hype gap+22
- Incentives66
- Confidence36
Orforglipron's approval takes peptide manufacturing and refrigeration off the constraint list. What replaces them is prescribing capacity in primary care and daily adherence.
Reality
- Evidence42
- Adoption48
- Hype gap+28
- Incentives58
- Confidence40
A Cambridge mouse study locates the GIP paradox in anatomy: agonists act through the brainstem, antagonists release a hypothalamic brake. Combination design becomes a targeting question.
Reality
- Evidence52
- Adoption34
- Hype gap+22
- Incentives62
- Confidence50